For the latest COVID-19 information for Massey, visit

News Center

Latest News

Massey researchers will further work in cancer immunotherapy and microRNA through career development program

Dec 17, 2018


Two VCU Massey Cancer Center clinician researchers have been awarded scholarships to participate in a mentored career development program designed to prepare them for the health care challenges of the future.

Mario Acunzo, Ph.D., and Guizhi (Julian) Zhu, Ph.D., both research members of Massey’s Developmental Therapeutics program, have been named Clinical Research KL2 Scholars at the VCU C. Kenneth and Dianne Wright Center for Clinical and Translational Research.  The KL2 program provides early-career researchers with dedicated time to help their findings benefit human health more quickly, while becoming successful, independent translational scientists.

“There is a national need to increase the clinical and translational research workforce and prepare the future generation of research leaders to address imminent health care challenges,” said VCU President Michael Rao, Ph.D. “Through opportunities like the KL2 research program, VCU is leveraging its interdisciplinary strengths in clinical research and community engagement to make meaningful improvements in patient care.”

Over the course of three years, the Clinical Research KL2 Scholars will receive financial support and protected time to focus on mentored, multidisciplinary research. The mentor-mentee relationship forms the basis for growth as an independent clinical and translational investigator, with mentors playing vital roles in fostering scholars’ career development, such as by helping them identify and pursue relevant educational and training opportunities.

Acunzo, an assistant professor of pulmonary disease and critical care medicine at the VCU School of Medicine, plans to investigate the role of microRNA editing in lung cancer progression. Similar to DNA, RNAs are one of the building blocks of the human body. MicroRNAs are a recently discovered class of non-coding RNAs that play key roles in gene expression regulation. In addition to understanding the role of microRNA editing in the development of disease, Acunzo plans to pursue microRNA editing as a potential biomarker to improve early detection of lung cancer. 

“Being a Clinical Research KL2 Scholar represents a great opportunity to advance my career as a researcher,” Acunzo said. “I look forward to having the protected time and support required to build a successful research program.”

Guizhi (Julian) Zhu, Ph.D.

Zhu, an assistant professor of pharmaceutics at the VCU School of Pharmacy, will spend three years developing next-generation nanomedicines for combination cancer immunotherapy. Nanomedicine is a branch of medicine that applies the knowledge and tools of nanotechnology to the prevention and treatment of disease.

“The KL2 scholarship will be a great opportunity and encouragement for me to establish my independent research team, and eventually translate our research development from the bench to the bedside,” Zhu said, adding that his goal is to develop innovative therapeutic strategies that use the body's immune response to enhance drug delivery, targeting and efficacy.

“We are delighted to welcome Julian and Mario to the KL2 scholars program,” said KL2 program co-director Patrick Nana-Sinkam, M.D., who is also a research member of Massey’s Cancer Cell Signaling and Cancer Prevention and Control programs. “In the next three years, they will have opportunities to engage with the Wright Center in areas including team science, community engagement, clinical trials and grant writing. By providing each of them with a tailored, mentored career development plan, we envision they will be well-positioned for research independence and for translating their research findings to improve human health throughout their careers.”

Earlier this year, the National Institutes of Health awarded the Wright Center with a five-year, $21.5 million Clinical and Translational Science Award — VCU’s largest NIH grant ever. The KL2 program is supported by the grant, which is administered through the NIH’s National Center for Advancing Translational Sciences. VCU is the only academic health center in Virginia to receive a Clinical and Translational Science Award.

Since first receiving the award in 2010, the Wright Center has provided 15 KL2 awards to a diverse team of research scholars who come from a variety of clinical research disciplines. Previous Clinical Research KL2 Scholars have included faculty members from the university’s School of Social Work, the College of Health ProfessionsDepartment of Physical Therapy, and the School of Dentistry.

Re-purposed from an article by Anne DreyfussC. Kenneth and Dianne Wright Center for Clinical and Translational Research

Written by: Wright Center

Related News

Center News & Funding

Massey physicians named Richmond’s “Top Docs”

Get access to new, innovative care

Get access to new, innovative care

Treatments in clinical trials may be more effective or have fewer side effects than the treatments that are currently available. With more than 200 studies for multiple types of cancers and cancer prevention, Massey supports a wide array of clinical trials.

Search clinical trials
Find a provider

Find a provider

Massey supports hundreds of top cancer specialists serving the needs of our patients. Massey’s medical team provides a wealth of expertise in cancer diagnosis, treatment, prevention and symptom management.

Find a provider